Previous Close | 1.4100 |
Open | 1.5400 |
Bid | 1.5300 x N/A |
Ask | 1.5500 x N/A |
Day's Range | 1.5400 - 1.6400 |
52 Week Range | 0.4660 - 1.6400 |
Volume | |
Avg. Volume | 32 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Amidst revenue decline and significant cash burn, Durect Corp reports promising clinical trial results and strategic FDA interactions.
Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?